Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

Similar articles for PubMed (Select 23730996)

1.
2.

Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.

Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M.

J Diabetes Complications. 2014 Sep-Oct;28(5):742-9. doi: 10.1016/j.jdiacomp.2014.04.003. Epub 2014 Apr 16.

3.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329. Epub 2014 Jul 12.

4.

Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study.

Zdarska DJ, Kvapil M, Rusavy Z, Krcma M, Broz J, Krivska B, Kadlecova P.

Wien Klin Wochenschr. 2014 Apr;126(7-8):228-37. doi: 10.1007/s00508-014-0508-6. Epub 2014 Feb 22.

PMID:
24563017
5.

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia.

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP.

Vasc Health Risk Manag. 2009;5(1):121-8. Epub 2009 Apr 8.

7.

Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.

Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J.

J Am Geriatr Soc. 2012 Jan;60(1):51-9. doi: 10.1111/j.1532-5415.2011.03773.x.

PMID:
22239291
8.

Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes.

Hershon KS, Blevins TC, Mayo CA, Rosskamp R.

Endocr Pract. 2004 Jan-Feb;10(1):10-7.

PMID:
15251616
9.

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.

Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C.

Nutr Metab Cardiovasc Dis. 2009 Oct;19(8):571-9. doi: 10.1016/j.numecd.2008.05.003. Epub 2008 Aug 3.

PMID:
18676131
10.

[Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].

Pesić M, Zivić S, Radenković S, Velojić M, Dimić D, Antić S.

Vojnosanit Pregl. 2007 Apr;64(4):247-52. Serbian.

PMID:
17580534
11.

Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.

Imbergamo MP, Amato MC, Sciortino G, Gambina M, Accidenti M, Criscimanna A, Giordano C, Galluzzo A.

Clin Ther. 2008 Aug;30(8):1476-84. doi: 10.1016/j.clinthera.2008.08.013.

PMID:
18803989
13.

Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.

Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.

Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1326-35. doi: 10.1002/pds.3534. Epub 2013 Oct 21.

14.

Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.

Testa MA, Gill J, Su M, Turner RR, Blonde L, Simonson DC.

J Clin Endocrinol Metab. 2012 Oct;97(10):3504-14. doi: 10.1210/jc.2012-1763. Epub 2012 Jul 31.

PMID:
22851487
15.

Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.

Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB.

Diabetes Care. 2003 Mar;26(3):799-804.

PMID:
12610040
16.

Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus.

Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K; Pediatric Study Group of Insulin Glargine.

J Pediatr Endocrinol Metab. 2002 Apr;15(4):369-76.

PMID:
12008682
17.

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB.

Diabetes Care. 2001 Apr;24(4):631-6.

PMID:
11315821
18.

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.

Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD.

Diabet Med. 2006 Mar;23(3):285-92.

PMID:
16492212
20.

Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain.

Delgado E; LAUREL Spain study investigators.

Int J Clin Pract. 2012 Mar;66(3):281-8. doi: 10.1111/j.1742-1241.2011.02880.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk